vTv Therapeutics Inc. (NASDAQ:VTVT – Get Free Report)’s stock price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $15.13 and traded as low as $13.70. vTv Therapeutics shares last traded at $14.10, with a volume of 2,305 shares.
vTv Therapeutics Stock Performance
The stock’s 50 day simple moving average is $14.80 and its 200 day simple moving average is $20.24. The firm has a market cap of $43.92 million, a P/E ratio of -1.65 and a beta of 0.63.
vTv Therapeutics (NASDAQ:VTVT – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.81) earnings per share for the quarter.
Institutional Investors Weigh In On vTv Therapeutics
vTv Therapeutics Company Profile
vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.
See Also
- Five stocks we like better than vTv Therapeutics
- ETF Screener: Uses and Step-by-Step Guide
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- CD Calculator: Certificate of Deposit Calculator
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- What is the Dogs of the Dow Strategy? Overview and Examples
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for vTv Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for vTv Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.